{
    "nct_id": "NCT05676749",
    "official_title": "C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* Able to understand and give written informed consent\n* Histologically and cytologically confirmed diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with adenocarcinoma or squamous histology\n* Planned for treatment with an anti-PD1 agent\n* Tumor accessible by surgery, previously not irradiated and ≥ 1.5 cm in diameter\n* Measurable disease after resection of tumor by RECIST 1.1\n* ECOG ≤ 1\n* Expected survival > 6 months\n* Adequate organ and marrow function\n* ECHO, MUGA or cardiac stress test within past 6 months showing LVEF >50% and without evidence of reversible ischemia\n* Pulmonary function tests within past 6 months showing DLCO >50% of predicted\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous treatment with PD1/PDL1 inhibitor for metastatic disease, Immune checkpoint blockade (ICB) given as part of definitive therapy for stage Ib-III disease with surgery or after chemo/radiation is acceptable if last dose of ICB is at least 6 months prior to enrollment in this study.\n* Known driver mutations such as EGFR, ALK, ROS1, RET, METex14, and NTRK alterations.\n* Current or prior use of any immunosuppressive medications within 14 days before tumor harvest\n* Known active CNS metastases which are symptomatic\n* History of leptomeningeal metastases\n* Uncontrolled intercurrent illness\n* Known history of HIV+ or AIDS, hepatitis C, acute or chronic active hepatitis B or other serious chronic infection\n* Live vaccine within 30 days of tumor harvest\n* History of allogeneic organ transplant\n* History of primary immunodeficiency\n* Hypersensitivity to anti-PD1 agent, cyclophosphamide, fludarabine, interleukin-2, gentamicin, or any excipient\n* Any condition that may interfere with evaluation of study treatment, safety or study results\n* Active infection that requires IV antibiotics within 7 days of tumor harvest\n* Unresolved greater than grade 1 toxicity (CTCAE v5.0) from previous therapy\n* History of interstitial pneumonitis of autoimmune etiology that is symptomatic or requires treatment\n* Pulmonary disease history requiring escalating amounts of oxygen > 2L\n* Known autoimmune conditions requiring systemic immune suppression therapy other than low dose prednisone or equivalent.\n* Other malignancy, other than cutaneous localized) that required active treatment in the last 2 years.\n* Women who are pregnant or lactating\n* Women of childbearing potential or fertile men who are unwilling to use effective contraception during study and 6 months after treatment",
    "miscellaneous_criteria": ""
}